BLA 022505 · Theratechnologies
Egrifta
Tesamorelin Acetate · Subcutaneous
NovelLast checked: Nov 20, 2026Latest source record: Mar 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Nov 10, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
2 Phase 3, 3 recruiting
FAERS reports
1,692
345 serious, 32 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 29, 2026.
EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA SV has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV. EGRIFTA SV is a growth hormone-releasing factor (GHRF) analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. ( 1 ) Limitations of use: Long-term cardiovascular safety of EGRIFTA SV has not been established. ( 1 ) Not indicated for weight loss management. ( 1 ) There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV. ( 1 )
Mechanism: In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF [see Clinical Pharmacology ( 12.2 )]. Growth hormone-releasing factor (GHRF), also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH), which is both anabolic and lipolytic. GH exerts its effects by interacting with specific receptors on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 10, 2010 Original approval · Type 1 - New Molecular Entity NovelSummary ReviewLetterLabel
2 products under this application
- EGRIFTA · TESAMORELIN ACETATE EQ 1MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
- EGRIFTA · TESAMORELIN ACETATE EQ 2MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tesamorelin" as an intervention, any sponsor and status, largest first.
- TH9507 in Patients With HIV-Associated LipodystrophyPivotal-lookingCompleted
TheratechnologiesIndustry
NCT00123253 · 412 participants · Start Jun 2005 · Primary completion Nov 2006
Drug: TH9507 · For: HIV Infections; Lipodystrophy
Sites: Los Angeles, California; Palm Springs, California; San Diego, California · 42 sites in all
- TH9507 Extension Study in Patients With HIV-Associated LipodystrophyPivotal-lookingCompleted
TheratechnologiesIndustry
NCT00608023 · 263 participants · Start Aug 2007 · Primary completion Oct 2008
Drug: Tesamorelin; Placebo for Tesamorelin · For: Lipodystrophy; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Indio, California · 47 sites in all
- SMART: Somatotrophics, Memory, and Aging Research TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT00257712 · 151 participants · Start Feb 2006 · Primary completion Dec 2011
Drug: TH9507 human growth hormone releasing hormone (GHRH) · For: Aging; Mild Cognitive Impairment
Sites: Seattle, Washington
- Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®Pivotal-lookingTerminated
TheratechnologiesIndustry
NCT01591902 · 129 participants · Start Jun 2012 · Primary completion May 2018
Drug: Tesamorelin; Placebo-Control · For: Diabetic Retinopathy; HIV
Sites: Phoenix, Arizona; Los Angeles, California; Palm Springs, California · 24 sites in all
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver DiseasePivotal-lookingRecruiting
Hudson BiotechIndustry
NCT07481734 · 120 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: Tesamorelin; Placebo · For: Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis
Sites: Shenzhen, China
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVPivotal-lookingRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06554717 · 100 participants (planned) · Start Jul 10, 2025 · Primary completion Jun 16, 2028
Drug: Tesamorelin; Placebo · For: HIV-1-infection; Frailty; Impaired Physical Function and 2 more
Sites: Aurora, Colorado; Boston, Massachusetts
University of California, San DiegoAcademic, hospital or other
NCT02572323 · 73 participants · Start Feb 15, 2017 · Primary completion Oct 15, 2023
Drug: Tesamorelin · For: Mild Cognitive Impairment
Sites: Los Angeles, California; Palm Springs, California; San Diego, California · 4 sites in all
Massachusetts General HospitalAcademic, hospital or other
NCT02196831 · 61 participants · Start Jul 1, 2015 · Primary completion Jan 16, 2019
Drug: tesamorelin; Placebo · For: Human Immunodeficiency Virus (HIV); Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH)
Sites: Bethesda, Maryland; Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue297
- incorrect dose administered164
- injection site pain160
- drug ineffective130
- product preparation issue122
- arthralgia113
- injection site bruising99
- weight increased99
- therapeutic product effect incomplete86
- injection site pruritus83
- wrong technique in product usage process79
- pain in extremity75
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 143 |
| 2021 | 171 |
| 2022 | 203 |
| 2023 | 348 |
| 2024 | 341 |
| 2025 | 233 |
| 2026 | 249 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Fourman LT, Billingsley JM, Agyapong G, et al. · JCI Insight 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Russo SC, Ockene MW, Arpante AK, et al. · AIDS 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Badran AS, Helal A, Shata KS, et al. · Obes Res Clin Pract 2026 · Meta-Analysis, Systematic Review
- The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
Makimura H, Murphy CA, Feldpausch MN, et al. · J Clin Endocrinol Metab 2014 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Ellis RJ, Vaida F, Hu K, et al. · J Infect Dis 2025 · Clinical Trial, Phase II, Multicenter Study
- Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
González-Sales M, Barrière O, Tremblay PO, et al. · Clin Pharmacokinet 2015 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Theratechnologies
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.